STOCK TITAN

Bicycle Therapeutics Plc - BCYC STOCK NEWS

Welcome to our dedicated news page for Bicycle Therapeutics Plc (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bicycle Therapeutics Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bicycle Therapeutics Plc's position in the market.

Rhea-AI Summary
Bicycle Therapeutics' lead therapy for metastatic bladder cancer, BT8009, has been selected for the FDA's CDRP Program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
conferences
-
Rhea-AI Summary
Bicycle Therapeutics to proceed with development of BT8009 for metastatic bladder cancer, aligns with FDA on Phase 2/3 trial design with potential accelerated approval. Trial to be initiated in 1Q 2024. Positive outcome may support broad metastatic bladder cancer population. Ongoing discussions for confirmatory trial design for previously treated cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.97%
Tags
none
-
Rhea-AI Summary
Bicycle Therapeutics to participate in fireside chat at Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
conferences
Rhea-AI Summary
Bicycle Therapeutics plc (NASDAQ: BCYC) reported financial results for Q2 2023, including advancements in clinical trials for BT8009, BT5528, and BT7480, strategic collaborations with Novartis, Bayer, and DKFZ, and the strengthening of the balance sheet with gross proceeds of approximately $230M. The company also enhanced its leadership team with the appointment of Alethia Young as the new CFO, bringing over 20 years of experience in the biopharma industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
-
Rhea-AI Summary
Bicycle Therapeutics plc (Nasdaq: BCYC) announced the closing of its underwritten public offering of 6,117,648 American Depositary Shares (ADSs) for gross proceeds of approximately $230.0 million. The offering was managed by Goldman Sachs & Co. LLC, Jefferies, and Leerink Partners. The ADSs were offered pursuant to a shelf registration statement on Form S-3ASR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
-
Rhea-AI Summary
Bicycle Therapeutics plc has announced the pricing of an underwritten public offering of 9,411,766 American Depositary Shares (ADSs) at a price of $21.25 per share, resulting in gross proceeds of approximately $200.0 million. The offering also includes an option for the underwriters to purchase up to 1,411,764 additional ADSs. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.32%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.32%
Tags
-
Rhea-AI Summary
Bicycle Therapeutics plc has appointed Alethia Young as its new Chief Financial Officer. Young brings extensive experience in the biopharma industry and will contribute to the company's clinical trials, commercialization preparation, and future growth. The company also announced the promotion of Travis Thompson to Senior Vice President, Chief Accounting Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
conferences
Bicycle Therapeutics Plc

Nasdaq:BCYC

BCYC Rankings

BCYC Stock Data

832.62M
6.17%
91.75%
6.71%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United Kingdom
Cambridge

About BCYC

bicycle therapeutics is a biotechnology company with big ambitions. we aim to revolutionise the pharmaceutical landscape with our disruptive technology and proprietary bicyclic peptide (bicycle®) product platform and to develop transformational new therapies for patients to improve future treatment options in oncology. bicycles, a new class of small molecular weight drug conjugates for oncology and other diseases, are designed to have superior targeting abilities and to be more efficacious and better tolerated than existing drug conjugate modalities. they combine the properties of several therapeutic entities in a single modality, exhibiting the affinity and selective pharmacology associated with antibodies; the distribution kinetics of small molecules, allowing rapid tumor penetration; and the “tuneable” pharmacokinetic half-life and renal clearance of peptides, sparing cytotoxin-payload derived liver and gastrointestinal toxicity. our unique ip is based on the work of scientific foun